DiaMedica Therapeutics progresses DM199 for ischemic stroke and preeclampsia, aiming to expand treatment windows. Read why ...

MICHAEL BECKLEY is Associate Professor of Political Science at Tufts University, a Nonresident Senior Fellow at the American ...

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns.

Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.

Demand for IT and business services in the Americas rose by double digits in the first quarter, despite growing economic uncertainty, according to the latest state-of-the-industry report from ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

Galapagos (GLPG) announced the departure of its CFO and COO, Thad Huston, effective as of August 1. Huston has decided to leave the company and ...

Cantor Fitzgerald upgraded Verve Therapeutics (VERV) to Overweight from Neutral.Stay Ahead of the Market: Discover outperforming stocks and ...

By: Cassidy Delamarter, University Communications and MarketingImagine walking into a space filled with innovative solutions to real-world problems ...